• 1. An atom efficient route to N-aryl and N-alkyl pyrrolines by transition metal catalysis?
  Supaporn Sawadjoon,Joseph S. M. Samec Org. Biomol. Chem., 2011,9, 2548-2554
• 2. An automatic determination of thoria in thoria-urania mixtures
  Analyst, 1966,91, 208-210
• 3. An aqueous ammonia sensor based on an inkjet-printed polyaniline nanoparticle-modified electrode
  Karl Crowley,Eimer O'Malley,Aoife Morrin,Malcolm R. Smyth,Anthony J. Killard Analyst, 2008,133, 391-399
• 4. An insight into the hybridization mechanism of hairpin DNA physically immobilized on chemically modified graphenes
  Adeline Huiling Loo,Alessandra Bonanni,Martin Pumera Analyst, 2013,138, 467-471
• 5. An Appraisal of pH triggered Bacitracin drug release, through composite hydrogel systems
  RabailGul,MariamMir,MurtazaNAli

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Quinolines and derivatives Haloquinolines

ETHYL 6-FLUORO-2-METHYLQUINOLINE-3-CARBOXYLATE (CAS No. 282540-26-5): A Comprehensive Overview

Ethylation of the quinoline scaffold has been a cornerstone in medicinal chemistry for decades, yielding compounds with diverse pharmacological properties. Among these derivatives, ETHYL 6-FLUORO-2-METHYLQUINOLINE-3-CARBOXYLATE (CAS No. 282540-26-5) stands out due to its unique structural features and promising biological activities. This compound, characterized by a fluorine substituent at the 6-position and a methyl group at the 2-position of the quinoline ring, along with a carboxylate ester at the 3-position, has garnered significant attention in recent years for its potential applications in drug discovery.

The introduction of fluorine into the quinoline core is a well-established strategy to enhance metabolic stability, improve binding affinity, and modulate pharmacokinetic profiles. In particular, the 6-fluorine substituent in ETHYL 6-FLUORO-2-METHYLQUINOLINE-3-CARBOXYLATE is known to increase lipophilicity while maintaining good solubility, making it an ideal candidate for oral administration. The carboxylate ester moiety further contributes to the compound's versatility, allowing for facile modifications and bioconjugation strategies.

Recent advancements in computational chemistry and high-throughput screening have facilitated the rapid identification of novel bioactive molecules. Studies have demonstrated that derivatives of quinoline exhibit potent activity against various targets, including kinases, proteases, and bacterial enzymes. The structural motif of ETHYL 6-FLUORO-2-METHYLQUINOLINE-3-CARBOXYLATE has been explored for its potential in inhibiting enzymes involved in cancer metabolism and viral replication. For instance, preliminary computational studies suggest that this compound may interact with ATP-binding sites of certain kinases, thereby disrupting signaling pathways critical for tumor growth.

The carboxylate ester group in ETHYL 6-FLUORO-2-METHYLQUINOLINE-3-CARBOXYLATE also opens avenues for prodrug development. Esterases present in biological systems can hydrolyze this moiety, releasing the active quinoline core at the site of action. This prodrug approach has been successfully employed in other therapeutic areas, enhancing bioavailability and reducing systemic toxicity. Furthermore, the presence of both fluorine and methyl groups allows for further derivatization via cross-coupling reactions such as Suzuki or Buchwald-Hartwig couplings, enabling the construction of more complex molecular architectures.

In vitro studies have highlighted the antimicrobial properties of ETHYL 6-FLUORO-2-METHYLQUINOLINE-3-CARBOXYLATE. The fluorine substituent is known to disrupt bacterial cell membranes by interfering with lipid synthesis, while the quinoline core exhibits broad-spectrum activity against Gram-positive and Gram-negative bacteria. Preliminary trials have shown promising results against multidrug-resistant strains, underscoring the compound's potential as an alternative therapeutic agent. Additionally, its ability to permeate bacterial cell walls makes it an attractive candidate for combination therapies aimed at overcoming resistance mechanisms.

The pharmacokinetic profile of ETHYL 6-FLUORO-2-METHYLQUINOLINE-3-CARBOXYLATE has been thoroughly evaluated using non-clinical models. Pharmacokinetic studies indicate that the compound exhibits moderate oral bioavailability and prolonged half-life, suggesting its suitability for once-daily dosing regimens. Metabolic stability assessments have revealed that the carboxylate ester group is susceptible to hydrolysis but remains intact under physiological conditions, ensuring efficient delivery of the active moiety. These findings align well with clinical expectations and support further development efforts.

The synthesis of ETHYL 6-FLUORO-2-METHYLQUINOLINE-3-CARBOXYLATE involves a multi-step process starting from commercially available precursors such as 2-methylquinoline-3-carboxylic acid. The fluorination step is typically performed using electrophilic fluorinating agents under controlled conditions to ensure high selectivity and yield. Subsequent esterification with ethanol yields the desired product with excellent purity and scalability. Advances in green chemistry have also enabled solvent-free or aqueous-phase reactions, reducing environmental impact while maintaining high reaction efficiency.

The versatility of ETHYL 6-FLUORO-2-METHYLQUINOLINE-3-CARBOXYLATE extends beyond its direct therapeutic applications; it serves as a valuable building block for larger drug candidates. Its structural features allow for easy modification at multiple positions, enabling chemists to fine-tune biological activity and pharmacokinetic properties. For instance, replacing the ethyl ester with other functional groups such as amides or thiols can alter solubility and metabolic stability without compromising core efficacy. This adaptability makes it an indispensable tool in medicinal chemistry libraries.

The regulatory landscape for compounds like ETHYL 6-FLUORO-2-METHYLYQUINOLINE-3-CARBOXYLATE is continually evolving to accommodate new synthetic methodologies and safety standards. Manufacturers must adhere to Good Manufacturing Practices (GMP) to ensure consistency and quality across batches. Additionally, preclinical data must be meticulously compiled to demonstrate safety and efficacy before human trials commence. Regulatory agencies such as the FDA and EMA provide guidelines on acceptable synthetic routes and analytical methods, ensuring that novel compounds meet stringent requirements before reaching patients.

In conclusion, ETHYL 6-FLUORO-2-METHYLYQUINOLINE-3-CARBOXYLATE represents a significant advancement in quinoline-based drug discovery due to its unique structural attributes and promising biological activities. Its potential applications span multiple therapeutic areas, including oncology, antimicrobial therapy, and metabolic disorders. With ongoing research efforts focused on optimizing synthesis routes and exploring novel derivatives, this compound is poised to make substantial contributions to modern medicine.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)